Answers are grounded in this paper and cite their sources.
Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents has become routine in the management of neovascular age-related macular degeneration (nAMD), diabetic macular edema, ...
No takes yet. Share an insight, caveat, or question.
Knickelbein et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: